Morgan Stanley Sees Downside to 2026-27 Consensus for Novo Amid Competition and Patent Risks
Novo Nordisk was downgraded because key drug sales (Ozempic/Wegovy) are slowing. Competition and future patent loss are hurting the stock.
/ 74 items
#NVO↓
Massive New Tariffs: How Trump’s Latest Duties Hit Drugs, Trucks, and Furniture
President Trump is hitting imports with massive new tariffs starting October 1st, targeting branded drugs (100%), heavy trucks (25%), and furniture.
Pfizer Acquires Metsera for Obesity Drug Pipeline Expansion
Pfizer is buying Metsera for $4.9 billion to gain promising new obesity drugs. The portfolio includes four clinical treatments, like once-a-month shots and future oral pills, aiming for better efficacy and easier patient use to fight the growing obesity epidemic.
Wegovy Pill Matches Injectable Weight-Loss Efficacy
The "Wegovy in a pill" (oral semaglutide 25 mg) shows huge promise for weight loss! Patients lost an average of 16.6% body weight, comparable to the injection. It's the first oral GLP-1 for weight management, offering convenience, and awaits FDA approval.
Novo Plans to Seek U.S. Approval for Its High-Dose Obesity Shot
Novo Nordisk is boosting its weight-loss efforts! They'll seek US approval for a high-dose Wegovy to match Lilly's Zepbound and are developing a pill version. They're also testing a new compound, cagrilintide, to regain market leadership.
Wegovy Outperforms Competitors in Cardiovascular Risk Reduction
Novo Nordisk's Wegovy showed a 57% greater heart attack/stroke/death risk reduction vs. Eli Lilly's GLP-1s (Mounjaro/Zepbound) in overweight/obese patients with cardiovascular disease but no diabetes. This suggests unique heart benefits for semaglutide, potentially increasing insurance coverage.